Keywords
Different clinical stages
Chronic myeloid leukemia
Clinical efficacy
Submitted : 2022-08-06
Accepted : 2022-08-21
Published : 2022-09-05
Abstract
Objective: To study the efficacy of dasatinib treatment in different clinical stages of patients with chronic myeloid leukemia (CML). Methods: A total of 80 patients with chronic myeloid leukemia (CML) were selected for experimental research. According to different clinical stages, they were divided into chronic phase, accelerated phase and blast phase, and all of them were treated with dasatinib. Results: The complete cytogenetic response remission rate, complete hematologic remission rate, and major molecular biological remission rate in the chronic phase were significantly higher. Besides, the overall survival time and relapse-free survival time in the chronic phase were significantly longer, and the mortality during the follow-up period in the chronic phase was also significantly higher. Furthermore, the incidence of hematological adverse reactions of grades ? to ? in the chronic phase was significantly lower compared with the corresponding data of patients in the accelerated phase and blast phase with P<0.05. Conclusion: Different clinical stages of CML patients have different curative effects of dasatinib, which can effectively treat patients in chronic stage.
References
Liu Q, Xu J, Wu J, et al., 2022, Efficacy and Influencing Factors of Second-Line Nilotinib and Third-Line Dasatinib on Chronic Myeloid Leukemia that Failed First and Second-Line Therapy. Chinese Journal of Experimental Hematology, 30(1): 30–35. https://doi.org/10.19746/j.cnki.issn1009-2137.2022.01.006
Dai L, Tu X, Cai B, 2018, Clinical Study of Dasatinib in the Treatment of Patients with Chronic Myeloid Leukemia in Different Clinical Stages. Journal of Oncology, 24(10): 997–1001. https://doi.org/10.11735/j.issn.1671-170X.2018.10.B012
Qin S, Meng D, Gong W, et al., 2021, Pharmaceutical Care of Patients with Chronic Myeloid Leukemia Combined with Lung Cancer with Targeted Drug Combination Therapy. Medicine Herald, 40(4): 538–541. https://doi.org/10.3870/j.issn.1004-0781.2021.04.021
Zheng J, 2021, Retrospective Analysis of Second-Line Treatment of Chronic Myeloid Leukemia with Nilotinib and Dasatinib, dissertation, Hebei Medical University.
Deng M, 2021, Progress in Tyrosine Kinase Inhibitor Therapy for Childhood Chronic Myeloid Leukemia. Journal of Pediatric Pharmacy, 27(2): 55–59. https://doi.org/10.13407/j.cnki.jpp.1672- 108X.2021.02.017
Genaguli A, 2021, Clinical Observation of Interferon Combined with Dasatinib in the Treatment of Chronic Myeloid Leukemia. World Latest Medical Information Digest, 21(59): 208–209. https://doi.org/10.3969/j.issn.1671-3141.2021.59.103
Lu R, Su P, 2021, Data Analysis of a Case of Chronic Myeloid Leukemia Blast with T-Cell Lymphoblastic Lymphoma. Frontiers in Medicine, 11(27):187–89.
Yu D, Cheng H, Guo J, et al., 2021, Preliminary Results of a Prospective Randomized Controlled Multicenter Clinical Study of Dasatinib 70 mg/D Versus 100 mg/D in the First-Line Treatment of Patients with Chronic Myeloid Leukemia in Chronic Phase. Journal of Clinical Hematology, 34(7):472?476. https://doi.org/10.13201/j.issn.1004-2806.2021.07.005
Zhang R, Ren Y, Zhang X, et al., 2021, Analysis of Clinical Features of Chronic Myeloid Leukemia in Children with Acute Lymphoblastic Leukemia First Diagnosed. International Journal of Pediatrics, 48(4): 286–290. https://doi.org/ 10.3760/cma.j.issn.1673-4408.2021.04.016
Chen J, Zhang Y, Yang W, 2021, Analysis of the Clinical Efficacy of Huanglian Jiedu Decoction Combined with Dasatinib in the Treatment of Chronic Myeloid Leukemia. Marriage and Childhood and Health, 2021(21): 95–96.
Wang L, 2020, Comparison of Dasatinib and Nilotinib in the Treatment of Chronic Myeloid Leukemia with Imatinib Resistance or Intolerance. China Health Nutrition, 30(6): 266.
Wang X, Zhang Y, Ning H, et al., 2020, Rapid Health Technology Evaluation of Dasatinib in the Treatment of Chronic Myeloid Leukemia. China Modern Applied Pharmacy, 37(14): 1755–1759. https://doi.org/10.13748/j.cnki.issn1007-7693.2020.14.017
Wang L, Sun W, Yang Z, et al., 2020, Application of HPLC-MS/MS Method In Monitoring Blood Concentration of CML Patients Treated with Imatinib, Dasatinib and Nilotinib. Laboratory Medicine and Clinical, 17(14): 1992–1996. https://doi.org/10.3969/j.issn.1672-9455.2020.14.014
Deng Q, Wang E, Wu X, et al., 2020, Combination of Axitinib and Dasatinib in the Treatment of a Case of Chronic Myeloid Leukemia with BCR-ABL1 T315I Mutation. Journal of Central South University (Medical Edition), 45(7): 874–880. https://doi.org/10.11817/j.issn.1672-7347.2020.190116
Yang L, Liu W, Sun Q, et al., 2020, Predictive Value of NK Cell Absolute Value on TKI Treatment Response in Newly Diagnosed Chronic Myeloid Leukemia Patients in Chronic Phase Journal of Nanjing Medical University (Natural Science Edition), 40(7): 991–995. https://doi.org/10.7655/NYDXBNS20200711
Qiao C, Yan X, 2020, Analysis of the Effect of Second-Generation Tyrosine Kinase Inhibitor Combined with Imatinib in the Treatment of Elderly Chronic Myeloid Leukemia. China Geriatric Health Medicine, 18(3): 59–60 + 63. https://doi.org/10.3969/j.issn.1672-2671.2020.03.021
Yuan T, Lai Y, Qin Y, et al., 2020, Efficacy and Influencing Factors of Nilotinib and Dasatinib as Second and Third-line Drugs in Patients with Chronic Myeloid Leukemia in Chronic Phase and Accelerated Phase. Zhonghua Blood Journal of Science, 41(2): 93–99. https://doi.org/10.3760/cma.j.issn.0253-2727.2020.02.002
Chen S, Zhang J, Li Y, et al., 2020, Chimeric Antigen Receptor T Cell Therapy for a Case of Relapsed and Refractory Acute B Lymphocytic Leukemia with T315I Mutation and Review of Literature. Leukemia Lymphoma, 29(3): 170–174. https://doi.org/10.3760/cma.j.cn115356-20190824-00162
Yang F, Zhang L, Shen Y, et al., 2020, Research Progress of BCR-ABL Tyrosine Kinase Inhibitor Combination Therapy in the Treatment of Chronic Myeloid Leukemia. China Journal of New Drugs and Clinical Medicine, 39(2):71–75. https://doi.org/10.14109/j.cnki.xyylc.2020.02.02
Li Z, Ge X, 2020, Analysis of Clinical Features and Treatment of Chronic Myeloid Leukemia. Chinese Medicine, 15(2): 280–283. https://doi.org/10.3760/j.issn.1673-4777.2020.02.029